Asea/Afscme Local 52 Health Benefits Trust v. Abbott Laboratories

CourtDistrict Court, N.D. Illinois
DecidedJune 18, 2018
Docket1:17-cv-06704
StatusUnknown

This text of Asea/Afscme Local 52 Health Benefits Trust v. Abbott Laboratories (Asea/Afscme Local 52 Health Benefits Trust v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Asea/Afscme Local 52 Health Benefits Trust v. Abbott Laboratories, (N.D. Ill. 2018).

Opinion

UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION ASEA/AFSCME LOCAL HEALTH 52 ) HEALTH BENEFITS TRUST, individually ) and on behalf of a class of similarly situated ) Case No. 17-cv-6704 third party payors, ) ) Judge Sharon Johnson Coleman Plaintiff, ) ) v. ) ) ABBOTT LABORATORIES, an Illinois ) corporation, and ST. JUDE MEDICAL, LLC, a ) Delaware corporation, ) ) Defendants. )

MEMORANDUM OPINION AND ORDER The plaintiff, the ASEA/AFSCME Local 52 Health Benefits Trust (“ASEA”), brings this action against Abbott Laboratories (“Abbott”) and St. Jude Medical, LLC (“St. Jude”), alleging that the defendants produced a defective product and concealed that products’ defects from the FDA and the public. The defendants now move this Court to dismiss ASEA’s claims for lack of subject matter jurisdiction, for lack of personal jurisdiction, for improper venue, or for failure to state a claim, or, alternatively, ask this Court to transfer this case to another venue. For the reasons set forth herein, the defendants’ motion to dismiss for lack of personal jurisdiction and improper venue [37] is granted, and the remaining motions [35, 39] are denied without prejudice as moot. Background The following facts from the plaintiff’s first amended complaint are accepted as true for the purpose of the present motion. St. Jude manufactures a variety of medical devices to treat cardiac conditions, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). Both ICDs and CRT-Ds are surgically implantable devices that use electrical impulses to moderate irregular heart rhythms. These devices are powered by lithium batteries. When their battery runs low, they are programed to provide one month of vibratory warnings prior to a battery failure. Unfortunately, a number of St. Jude’s ICD and CRT-D products (“the affected products”) suffered from a battery defect capable of causing rapid battery failure. This defect, as well as its root cause, was first reported by St. Jude’s battery supplier in 2011. At that time, St. Jude did not report or investigate the problem, but instead represented that the cause of unexpected battery depletions

could not be confirmed. St. Jude subsequently received forty-two product reports between 2011 and 2014 indicating that the affected products might be subject to premature battery depletion. Notwithstanding these reports, St. Jude repeatedly claimed that the cause of the potential defect could not be determined and failed to rigorously review the available information. In 2014 a patient’s death was linked to a premature battery failure in St. Jude’s products, and a published journal article identified the cause of the premature battery failures in St. Jude’s devices. In 2015, St. Jude and Abbott began negotiations regarding a potential merger. Prior to the merger, which occurred on March of 2016, Abbott initiated a detailed due-diligence review of St. Jude. Following that process and the merger, St. Jude opened new investigations into the battery failure issue. These investigations were much more rigorous than prior efforts, and in August 2016 St. Jude decided to recall the defective devices. On October 10, 2016, the FDA initiated a class 1 recall of 251,346 St. Jude products made before May of 2015. The recall, however, only covered patients’ out-of-pocket expenses, and does not reimburse third-party-payers for the cost of

monitoring and replacing the defective products. The plaintiff, a third-party payer of medical expenses based in Alaska, alleges that the defendants’ breached their express and implied warranties by selling a defective product and asserts product liability and manufacturing defect claims, as well as claims of negligence, failure to warn, misrepresentation, omission, and the violation of multiple consumer protection acts based on St. Jude’s failure to timely disclose the product defect. Discussion The defendants contend that this Court lacks personal jurisdiction over St. Jude. When a motion to dismiss is based on lack of personal jurisdiction, the plaintiff bears the burden of making a prima facie showing establishing jurisdiction over each defendant. Nelson v. Park Indus., Inc., 717

F.2d 1120, 1123 (7th Cir. 1983). The facts pertaining to jurisdiction set forth in the plaintiff’s complaint are assumed to be true unless controverted by affidavit, and all factual conflicts must be resolved in the plaintiff’s favor. John Walker & Sons, Ltd. v. DeMert & Dougherty, Inc., 821 F.2d 399, 402 (7th Cir. 1987). For a Court to exercise personal jurisdiction consistent with due process the defendant must have sufficient contacts with the forum state such that the maintenance of the suit “does not offend traditional notions of fair play and substantial justice.” Int’l Shoe Co. v. Washington, 326 U.S. 310, 316, 66 S.Ct. 154, 90 L.Ed. 95 (1945). Personal jurisdiction exists in two forms; general jurisdiction and specific jurisdiction. Goodyear Dunlop Tires Operations, S.A. v. Brown, 564 U.S. 915, 919, 131 S.Ct. 2846, 180 L.Ed.2d 796 (2011). General jurisdiction extends beyond the boundaries of an individual lawsuit, and exists when a corporation engages in “continuous corporate operations within a state . . . so substantial and of such a nature as to justify suit . . . on causes of action arising from dealings entirely distinct from those activities.” Daimler AG v. Bauman, 571 U.S. 117, 138, 134 S.Ct.

746, 187 L.Ed.2d 624 (2014). The Supreme Court has identified only two conditions where that condition would be met: the defendant’s place of incorporation and the principle place of the defendant’s business. Kipp v. Ski Enter. Corp. of Wis., Inc. , 783 F.3d 695, 698 (7th Cir. 2015) (citing Daimler, 571 U.S. at 137–38). General jurisdiction may also be found elsewhere when the corporate defendant’s activities in a state are so substantial that the corporation is “fairly regarded as at home” in the state. Id. Here, it is undisputed that St. Jude Medical, Inc. was incorporated and headquartered in Minnesota and that, following the merger with Abbott, St. Jude Medical, LLC was incorporated in Delaware and headquartered in Minnesota. ASEA, however, contends that since the merger St. Jude has operated as Abbott’s corporate alter ego. ASEA therefore contends that St. Jude should be

treated as an extension of Abbott, which is incorporated and headquartered in Illinois. The “alter ego” or “sham corporation” exception applies where a plaintiff alleges that a defendant corporation is a mere shell used for the benefit of other defendants. The determination of whether or not to pierce the corporate veil is determined by applying the law of the state of incorporation. Wachovia Securities, LLC v. Banco Panamericano, Inc., 674 F.3d 743, 751 (7th Cir. 2012); Stromberg Metal Works, Inc. v. Press Mechanical, Inc., 77 F.3d 928, 933 (7th Cir. 1996). St. Jude Medical, LLC is incorporated in Delaware, so the Court applies Delaware law. Accordingly, the plaintiff must plead facts supporting an inference that Abbott, through St. Jude, has created a sham entity designed to defraud investors and creditors. Crosse v. BCBSD, Inc., 836 A.2d 492, 496 (Del. 2003). Under Delaware law, courts disregard the corporate form only in exceptional cases. Eagle Air Transp., Inc.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Goodyear Dunlop Tires Operations, S. A. v. Brown
131 S. Ct. 2846 (Supreme Court, 2011)
Crosse v. BCBSD, INC.
836 A.2d 492 (Supreme Court of Delaware, 2003)
Wachovia Securities, LLC v. Banco Panamericano, Inc.
674 F.3d 743 (Seventh Circuit, 2012)
LaSalle National Bank v. Vitro, Sociedad Anonima
85 F. Supp. 2d 857 (N.D. Illinois, 2000)
Daimler AG v. Bauman
134 S. Ct. 746 (Supreme Court, 2014)
Walden v. Fiore
134 S. Ct. 1115 (Supreme Court, 2014)
William Kipp v. Ski Enterprise Corporation
783 F.3d 695 (Seventh Circuit, 2015)
Greene v. Mizuho Bank, Ltd.
169 F. Supp. 3d 855 (N.D. Illinois, 2016)
City of Greenville v. Syngenta Crop Protection, Inc.
830 F. Supp. 2d 550 (S.D. Illinois, 2011)
John Walker & Sons, Ltd. v. DeMert & Dougherty, Inc.
821 F.2d 399 (Seventh Circuit, 1987)

Cite This Page — Counsel Stack

Bluebook (online)
Asea/Afscme Local 52 Health Benefits Trust v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aseaafscme-local-52-health-benefits-trust-v-abbott-laboratories-ilnd-2018.